CYP1A1 and pulmonary arterial hypertension: Omics-based approaches, such as metabolomic profiling of PAH-CYP1A1 DNA adducts, provide quantitative exposure biomarkers that can link environmental PAH levels to metabolic dysfunction (Samer et al., 2020).